IL10 and ulcerative colitis: This shift reduces pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), elevates anti-inflammatory IL-10, and mitigates mucosal damage, positioning miR-223 as a potent therapeutic candidate for ulcerative colitis (UC).